Ifoside M Injection contains Ifosfamide 1 gm and Mesna 100 mg, a combination formulation used in the treatment of various cancers as part of established chemotherapy protocols. Ifosfamide acts as the primary anticancer agent, while Mesna is included to help protect the urinary tract from certain toxic effects associated with Ifosfamide therapy. The combination plays an important role in oncology practice by providing effective cancer treatment along with supportive protection during chemotherapy administration.

Ifosfamide belongs to the class of alkylating agents and works by interfering with the DNA of rapidly dividing cancer cells. This action helps prevent cancer cell growth and multiplication, ultimately leading to cell death. Due to its broad anticancer activity, Ifosfamide is widely utilized in the management of multiple solid tumors and hematological malignancies. The addition of Mesna enhances treatment safety by helping neutralize harmful metabolites that may affect the urinary bladder.

The injection is commonly prescribed in the treatment of sarcomas, testicular cancer, lymphomas, ovarian cancer, lung cancer, and various other malignancies as determined by an oncology specialist. It is frequently administered in combination with other anticancer medicines to improve therapeutic outcomes. Careful medical supervision and monitoring are essential throughout treatment to ensure optimal effectiveness and minimize treatment-related complications.

With the increasing demand for comprehensive oncology treatment solutions, Ifoside M Injection holds significant value in the anticancer segment. Its established role in chemotherapy protocols, broad clinical utility, and consistent demand in specialized oncology centers make it a valuable product for retailers and distributors. The product offers strong business potential and sustainable growth opportunities within the expanding oncology pharmaceutical market.

Ifoside M Injection may cause nausea, vomiting, fatigue, loss of appetite, hair loss, diarrhea, weakness, low blood cell counts, and injection site reactions. Bone marrow suppression, infections, kidney function abnormalities, urinary tract irritation, neurological symptoms, and bleeding tendencies may occur and require close medical monitoring.

Ifoside M Injection is indicated for the treatment of sarcomas, testicular cancer, lymphomas, ovarian cancer, lung cancer, and other malignancies as determined by an oncology specialist. It helps control cancer cell growth while supporting safer administration of Ifosfamide-containing chemotherapy regimens.

This medication should be administered only by qualified healthcare professionals experienced in cancer chemotherapy. Regular monitoring of blood counts, kidney function, liver function, hydration status, and overall patient condition is essential during treatment. Patients should immediately report fever, unusual bleeding, urinary symptoms, severe fatigue, confusion, or signs of infection. Treatment should always be individualized according to the patient's condition and response to therapy.

Store in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep the vial in its original packaging until use and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of deterioration.